An interim FTC report alleges that PBMs aggressively steer patients toward high-cost specialty drugs and preferred pharmacies to maximize profits. For example, a generic leukemia drug costing $66 was reimbursed at $2,700. Former FDA Commissioner Scott Gottlieb explains how the "back-ended rebate" system allows PBMs and insurers to profit while patients pay high out-of-pocket costs at the pharmacy counter.
